Literature DB >> 21205225

Monosodium glutamate neonatal intoxication associated with obesity in adult stage is characterized by chronic inflammation and increased mRNA expression of peroxisome proliferator-activated receptors in mice.

Ruben Roman-Ramos1, Julio C Almanza-Perez, Rebeca Garcia-Macedo, Gerardo Blancas-Flores, Angeles Fortis-Barrera, Edgar I Jasso, Mario Garcia-Lorenzana, Alfonso E Campos-Sepulveda, Miguel Cruz, Francisco J Alarcon-Aguilar.   

Abstract

The monosodium glutamate (MSG) neonatal administration in mice provides a model of obesity with impaired glucose tolerance (IGT) and insulin resistance. However, the inflammatory profile of cytokines produced from fat tissue and its relationship to the metabolic dysfunction induced by MSG have not yet been revealed. The aim of this study was to establish the inflammatory profile attributed to MSG by measuring the expression of adipokines in visceral fat and serum of 19-week-old mice as well as the peroxisome proliferator-activated receptors alpha and gamma (PPARα and γ). Some metabolic and biochemical parameters were also quantified. The MSG increased mRNA expression of interleukin-6 (IL-6), tumour necrosis factor-alpha (TNFα), resistin and leptin, but adiponectin did not exhibit any changes. In addition, impaired glucose tolerance, increased levels of insulin, resistin and leptin were observed in serum. Both PPARα and PPARγ were activated in MSG-induced obese mice, which might explain its inflammatory profile. However, liver transaminases were severely depressed, indicating that MSG may also induce liver injury, contributing to inflammation. The MSG neonatal neuro-intoxication in mice may thus provide a model of obesity and inflammation characterized by the dual activation of PPARα and PPARγ, which might offer new insights into the mechanism of inflammatory diabetes in obesity leading to steatohepatitis, as well as a suitable model to study the role of new therapeutic agents to prevent or reduce insulin resistance, the inflammatory state and liver steatosis.
© 2011 The Authors. Basic & Clinical Pharmacology & Toxicology © 2011 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205225     DOI: 10.1111/j.1742-7843.2011.00671.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  16 in total

1.  Nutrigenomics of hepatic steatosis in a feline model: effect of monosodium glutamate, fructose, and Trans-fat feeding.

Authors:  Kate S Collison; Marya Z Zaidi; Soad M Saleh; Nadine J Makhoul; Angela Inglis; Joey Burrows; Joseph A Araujo; Futwan A Al-Mohanna
Journal:  Genes Nutr       Date:  2011-12-06       Impact factor: 5.523

2.  A review of the alleged health hazards of monosodium glutamate.

Authors:  Anca Zanfirescu; Anca Ungurianu; Aristides M Tsatsakis; George M Nițulescu; Demetrios Kouretas; Aris Veskoukis; Dimitrios Tsoukalas; Ayse B Engin; Michael Aschner; Denisa Margină
Journal:  Compr Rev Food Sci Food Saf       Date:  2019-05-08       Impact factor: 12.811

3.  Taurine supplementation regulates Iκ-Bα protein expression in adipose tissue and serum IL-4 and TNF-α concentrations in MSG obesity.

Authors:  Luiz Carlos Caetano; Maria Lúcia Bonfleur; Rosane Aparecida Ribeiro; Tarlliza Romanna Nardelli; Camila Lubaczeuski; Juliana do Nascimento da Silva; Everardo Magalhães Carneiro; Sandra Lucinei Balbo
Journal:  Eur J Nutr       Date:  2015-11-30       Impact factor: 5.614

4.  Benefits of L-alanine or L-arginine supplementation against adiposity and glucose intolerance in monosodium glutamate-induced obesity.

Authors:  Thiago R Araujo; Israelle N Freitas; Jean F Vettorazzi; Thiago M Batista; Junia C Santos-Silva; Maria L Bonfleur; Sandra L Balbo; Antonio C Boschero; Everardo M Carneiro; Rosane A Ribeiro
Journal:  Eur J Nutr       Date:  2016-06-17       Impact factor: 5.614

Review 5.  Early life factors and type 2 diabetes mellitus.

Authors:  Xinli Jiang; Huijie Ma; Yan Wang; Yan Liu
Journal:  J Diabetes Res       Date:  2013-12-16       Impact factor: 4.011

6.  Reference genes for real-time PCR quantification of messenger RNAs and microRNAs in mouse model of obesity.

Authors:  Petra Matoušková; Hana Bártíková; Iva Boušová; Veronika Hanušová; Barbora Szotáková; Lenka Skálová
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

7.  Biochemical alterations during the obese-aging process in female and male monosodium glutamate (MSG)-treated mice.

Authors:  René J Hernández-Bautista; Francisco J Alarcón-Aguilar; María Del C Escobar-Villanueva; Julio C Almanza-Pérez; Héctor Merino-Aguilar; Mina Konigsberg Fainstein; Norma E López-Diazguerrero
Journal:  Int J Mol Sci       Date:  2014-06-27       Impact factor: 5.923

8.  The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.

Authors:  Takayasu Ideta; Yohei Shirakami; Tsuneyuki Miyazaki; Takahiro Kochi; Hiroyasu Sakai; Hisataka Moriwaki; Masahito Shimizu
Journal:  Int J Mol Sci       Date:  2015-12-08       Impact factor: 5.923

9.  Extensive use of monosodium glutamate: A threat to public health?

Authors:  Kamal Niaz; Elizabeta Zaplatic; Jonathan Spoor
Journal:  EXCLI J       Date:  2018-03-19       Impact factor: 4.068

10.  SHYCD induces APE1/Ref-1 subcellular localization to regulate the p53-apoptosis signaling pathway in the prevention and treatment of acute on chronic liver failure.

Authors:  Jianxin Diao; Haiye Li; Wei Huang; Wenxiao Ma; Huan Dai; Yawei Liu; Ming Wang; He Yu Hua; Jinying Ou; Xiaomin Sun; Xuegang Sun; Yungao Yang
Journal:  Oncotarget       Date:  2017-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.